Next generation of fluorine-containing pharmaceuticals, compounds currently in phase II–III clinical trials of major pharmaceutical companies: new structural trends …

Y Zhou, J Wang, Z Gu, S Wang, W Zhu… - Chemical …, 2016 - ACS Publications
Fluoroorganic chemistry has become essential in the evolution of many different but
interconnected research fields. These include the development of new materials with a …

The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis

K Dheda, T Gumbo, G Maartens, KE Dooley… - The lancet Respiratory …, 2017 - thelancet.com
Global tuberculosis incidence has declined marginally over the past decade, and
tuberculosis remains out of control in several parts of the world including Africa and Asia …

[HTML][HTML] Global Tuberculosis Report 2020–Reflections on the Global TB burden, treatment and prevention efforts

J Chakaya, M Khan, F Ntoumi, E Aklillu… - International journal of …, 2021 - Elsevier
Abstract The October 2020 Global TB report reviews TB control strategies and United
Nations (UN) targets set in the political declaration at the September 2018 UN General …

[HTML][HTML] Global health burden of ambient PM2. 5 and the contribution of anthropogenic black carbon and organic aerosols

S Chowdhury, A Pozzer, A Haines… - Environment …, 2022 - Elsevier
Chronic exposure to fine particulate matter (PM 2. 5) poses a major global health risk,
commonly assessed by assuming equivalent toxicity for different PM 2. 5 constituents. We …

Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis

Z Lan, N Ahmad, P Baghaei, L Barkane… - The Lancet …, 2020 - thelancet.com
Background Treatment of multidrug-resistant tuberculosis requires long-term therapy with a
combination of multiple second-line drugs. These drugs are associated with numerous …

Advances in the development of new tuberculosis drugs and treatment regimens

A Zumla, P Nahid, ST Cole - Nature reviews Drug discovery, 2013 - nature.com
Despite the introduction 40 years ago of the inexpensive and effective four-drug (isoniazid,
rifampicin, pyrazinamide and ethambutol) treatment regimen, tuberculosis (TB) continues to …

The rise of multiple imputation: a review of the reporting and implementation of the method in medical research

P Hayati Rezvan, KJ Lee, JA Simpson - BMC medical research …, 2015 - Springer
Background Missing data are common in medical research, which can lead to a loss in
statistical power and potentially biased results if not handled appropriately. Multiple …

[HTML][HTML] New agents for the treatment of drug-resistant Mycobacterium tuberculosis

DT Hoagland, J Liu, RB Lee, RE Lee - Advanced drug delivery reviews, 2016 - Elsevier
Inadequate dosing and incomplete treatment regimens, coupled with the ability of the
tuberculosis bacilli to cause latent infections that are tolerant of currently used drugs, have …

Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid …

S Kadura, N King, M Nakhoul, H Zhu… - Journal of …, 2020 - academic.oup.com
Background Improved genetic understanding of Mycobacterium tuberculosis (MTB)
resistance to novel and repurposed anti-tubercular agents can aid the development of rapid …

Drug Resistance Mechanisms in Mycobacterium tuberculosis

JC Palomino, A Martin - Antibiotics, 2014 - mdpi.com
Tuberculosis (TB) is a serious public health problem worldwide. Its situation is worsened by
the presence of multidrug resistant (MDR) strains of Mycobacterium tuberculosis, the …